Discovery Investment Research Provides Update on Medexus Pharma
DIR Announces Availability of Research Update
PHOENIX, AZ / ACCESSWIRE / September 10, 2019 / Discovery Investment Research (DIR), an equity research firm specializing in micro and small-cap stocks, announces the availability of a research update on Medexus Pharma (PDDPF) (MDP). The update on Medexus Pharma, a specialty pharmaceutical company with operations in Canada and the United States, can be obtained by visiting DIR’s website ( www.discoveryinvresearch.com ). The following key attributes serve as the basis for DIR’s current recommendation:
Pediapharm is a specialty pharmaceutical company with operations in both Canada and the United States. The company markets several products aimed at niche markets for both children and adults, including pharmaceuticals for Rheumatoid Arthritis and other auto-immune disorders.
Roland Boivin Chief Financial Officer Pediapharm Inc. Tel.: 514-762-2626 ext. 202 E-mail: Frank Candido Direct Financial Strategies and Communication Inc. Tel. 514-969-5530 E-mail:
SOURCE: Discovery Investment Research
View source version on accesswire.com: